Financhill
Sell
28

SYRE Quote, Financials, Valuation and Earnings

Last price:
$22.70
Seasonality move :
0.26%
Day range:
$21.13 - $23.35
52-week range:
$20.07 - $47.97
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
799.55x
P/B ratio:
7.96x
Volume:
467.8K
Avg. volume:
589.1K
1-year change:
3.24%
Market cap:
$1.4B
Revenue:
$886K
EPS (TTM):
-$4.12

Analysts' Opinion

  • Consensus Rating
    Spyre Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 1 Hold rating, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $58.63, Spyre Therapeutics has an estimated upside of 151.93% from its current price of $23.27.
  • Price Target Downside
    According to analysts, the lowest downside price target is $40.00 representing 100% downside risk from its current price of $23.27.

Fair Value

  • According to the consensus of 10 analysts, Spyre Therapeutics has 151.93% upside to fair value with a price target of $58.63 per share.

SYRE vs. S&P 500

  • Over the past 5 trading days, Spyre Therapeutics has underperformed the S&P 500 by -1.66% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Spyre Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Spyre Therapeutics has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Spyre Therapeutics reported revenues of --.

Earnings Growth

  • Spyre Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Spyre Therapeutics reported earnings per share of -$1.06.
Enterprise value:
1.1B
EV / Invested capital:
--
Price / LTM sales:
799.55x
EV / EBIT:
--
EV / Revenue:
902.02x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-7.32x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $5.8M -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -$86.1M -$100M -$195.1M -$33.2M -$55.4M
EBITDA -$84.2M -$98.9M -$195.1M -$33.2M -$55.4M
Diluted EPS -$28.61 -$50.58 -$4.12 -$0.86 -$1.06
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $144.4M $117.5M $82.2M $205.9M $421.1M
Total Assets $155.6M $129.1M $91.6M $207.3M $421.1M
Current Liabilities $14.3M $20.4M $17.7M $44.9M $57.5M
Total Liabilities $19.4M $27M $24M $452.7M $93.7M
Total Equity $136.3M $102.1M $67.6M -$245.4M $327.4M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$81.3M -$87M -$151.2M -$34.6M -$29.4M
Cash From Investing $52.7M -$59.1M -$218M -$97.6M $42.7M
Cash From Financing $42.8M $197.5M $348.9M -$12.5M $12.8M
Free Cash Flow -$81.3M -$87M -$151.2M -$34.6M -$29.4M
SYRE
Sector
Market Cap
$1.4B
$43.3M
Price % of 52-Week High
48.51%
47.98%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
3.24%
-36.92%
Beta (5-Year)
2.850
0.753
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $23.11
200-day SMA
Sell
Level $28.69
Bollinger Bands (100)
Sell
Level 22.72 - 32.1
Chaikin Money Flow
Sell
Level -238.6M
20-day SMA
Buy
Level $22.25
Relative Strength Index (RSI14)
Buy
Level 51.90
ADX Line
Sell
Level 11.73
Williams %R
Neutral
Level -34.0611
50-day SMA
Sell
Level $23.66
MACD (12, 26)
Sell
Level -0.16
25-day Aroon Oscillator
Sell
Level -52
On Balance Volume
Neutral
Level 342.9M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (0.3702)
Sell
CA Score (Annual)
Level (-2.9616)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (7.007)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.

Stock Forecast FAQ

In the current month, SYRE has received 9 Buy ratings 1 Hold ratings, and 0 Sell ratings. The SYRE average analyst price target in the past 3 months is $58.63.

  • Where Will Spyre Therapeutics Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Spyre Therapeutics share price will rise to $58.63 per share over the next 12 months.

  • What Do Analysts Say About Spyre Therapeutics?

    Analysts are divided on their view about Spyre Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Spyre Therapeutics is a Sell and believe this share price will drop from its current level to $40.00.

  • What Is Spyre Therapeutics's Price Target?

    The price target for Spyre Therapeutics over the next 1-year time period is forecast to be $58.63 according to 10 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.

  • Is SYRE A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Spyre Therapeutics is a Buy. 9 of 10 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of SYRE?

    You can purchase shares of Spyre Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Spyre Therapeutics shares.

  • What Is The Spyre Therapeutics Share Price Today?

    Spyre Therapeutics was last trading at $22.70 per share. This represents the most recent stock quote for Spyre Therapeutics. Yesterday, Spyre Therapeutics closed at $23.27 per share.

  • How To Buy Spyre Therapeutics Stock Online?

    In order to purchase Spyre Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Will Palantir Stock Be Worth in 2030?
What Will Palantir Stock Be Worth in 2030?

Palantir Technologies (NYSE: PLTR) has emerged from a growth slowdown…

Is Rollins Stock a Buy, Sell or Hold?
Is Rollins Stock a Buy, Sell or Hold?

Pest control giant Rollins (NYSE:ROL) is the parent company of…

Why Did Bill Ackman Buy Uber?
Why Did Bill Ackman Buy Uber?

In early 2025, billionaire investor Bill Ackman, CEO of Pershing…

Stock Ideas

Buy
61
Is AAPL Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 39x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 110x

Sell
43
Is MSFT Stock a Buy?

Market Cap: $3T
P/E Ratio: 35x

Alerts

Buy
58
UPST alert for Feb 13

Upstart Holdings [UPST] is down 5.37% over the past day.

Buy
79
CFLT alert for Feb 13

Confluent [CFLT] is down 3.72% over the past day.

Buy
52
BL alert for Feb 13

BlackLine [BL] is up 0.61% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock